Immunotherapy is one of the pillars in the fight against cancer and aims to enable the body’s own immune system to fight a tumor.
Advances in ALL at ASH Meeting Include New Blinatumomab Data and More
In the phase III ECOG-ACRIN E1910 study presented at the American Society of Hematology (ASH) annual meeting, consolidation chemotherapy with blinatumomab (Blincyto) improved overall survival